UFP Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UFPT research report →
Range $252 – $344
Price Chart
About the company
UFP Technologies, Inc. specializes in the engineering and custom fabrication of components, subassemblies, finished products, and packaging, primarily utilizing advanced foams, films, and plastics. A significant portion of its business is dedicated to the medical sector, where its single-use and single-patient devices and parts are integral to a broad spectrum of applications, including general medical devices, disposable wound care, infection control, minimally invasive surgical tools, wearable technologies, orthopedic soft goods, and protective packaging for orthopedic implants.
- CEO
- Mitchell C. Rock
- IPO
- 1993
- Employees
- 4,846
- HQ
- Newburyport, MA, US
Get TickerSpark's AI analysis on UFPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.25B
- P/E
- 30.05
- Fwd P/E
- 29.59
- PEG
- 2.22
- P/S
- 3.55
- P/B
- 4.74
- EV/EBITDA
- 20.81
- Div Yield
- 0.00%
- Gross Margin
- 28.95%
- Op Margin
- 15.48%
- Net Margin
- 11.78%
- ROE
- 16.90%
- ROIC
- 13.18%
Latest fiscal year · YoY change
- Revenue
- $602.80M+19.5%
- Gross Profit
- $170.41M+16.2%
- Op Income
- $92.34M
- Net Income
- $68.31M+15.8%
- EPS
- $8.87+15.3%
- OCF Growth
- +38.0%
- FCF Growth
- +38.7%
- 52W High
- $342.11
- 52W Low
- $173.86
- 50D MA
- $294.44
- 200D MA
- $252.63
- Beta
- 1.10
- RSI (14)
- 50
- Avg Volume
- 110.83K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
UFP Technologies posted another strong quarter with double-digit sales growth, higher margins, and continued progress on its MedTech expansion and acquisition strategy.· November 4, 2026
- Third-quarter sales rose to $172.4 million, up 11.6%, with organic growth of 11.1%.
- Gross margin expanded to 29.4% from 27.7% a year ago, and adjusted EPS increased to $2.88.
- Growth was broad-based across MedTech, with strength in patient beds and handling, cardiovascular, infection control, and orthopedic submarkets.
- Management said AJR transfer work to the Dominican Republic is still behind schedule, with more activity expected to complete in 2027.
- The company highlighted CI Medical as a strategic add-on and said it is working to expand its credit facility to support more M&A.
Third-quarter 2026 sales were $172.4 million, up 11.6% year over year, with organic sales growth of 11.1%. Gross margin was 29.4%, versus 27.7% last year; adjusted operating margin was 17.5%; adjusted operating income grew 14.5%; and adjusted EPS was $2.88. Year to date, sales were $500.6 million, up 10.3%. Management said full-year-style guidance was not provided, but reiterated comfort with a 6% to 9% organic growth baseline and a 12% to 18% overall growth framework including acquisitions; it also said Q4 is traditionally softer and could be affected by holiday shutdowns in the Dominican Republic.
Mitch Rock emphasized broad-based demand and operational progress, saying the quarter reflected solid execution and steady movement on the long-term growth strategy. He pointed to scaling new programs in the Dominican Republic, margin improvement in legacy operations, and year-over-year progress at AJR, while acknowledging AJR transfers are still behind schedule. His tone was constructive and optimistic, especially about 2027, supported by customer relationships, new capacity, and an active acquisition pipeline.
Ronald Lataille quantified the quarter’s financial performance and the drivers behind it: sales up 11.6%, organic growth of 11.1%, gross margin up to 29.4% from 27.7%, adjusted operating margin at 17.5%, and adjusted EPS of $2.88. He said SG&A increased by $4.1 million to $23.2 million, largely due to about $1.9 million in wages and benefits for back-office investments and senior-management expansion, plus about $800,000 in noncash equity compensation partly tied to duplicate CEO equity costs. He also said the company generated about $38.5 million in cash from operations, spent $3.9 million on capex, and ended with leverage well under 1x.
Analysts focused on the pace of AJR offshore transfers, asking whether final programs could move this year or in 2027; management said the business is still being aligned with customer priorities and that additional transfer activity is expected in 2027. Questions also centered on capital allocation, with management saying the company is prioritizing organic growth but expects acquisitions to be a bigger use of capital given its capital-light model. On growth expectations, management reiterated comfort with the 6% to 9% organic baseline and said Q4 is usually softer, partly because of Dominican Republic holiday shutdowns.
The call showed broad, double-digit sales growth, improving margins, and strong cash generation, suggesting the core business remains healthy. Management also sounded confident about 2027, citing new programs, additional capacity, an active M&A pipeline, and further benefits from products and platforms that are gaining adoption.
AJR remains a drag in the sense that the transfer of higher-labor products to the Dominican Republic is still not complete and is now expected to continue into 2027. Management also signaled Q4 seasonality and holiday shutdowns could slow growth, and SG&A is rising because the company is investing ahead of growth and carrying some one-time or permanent cost increases.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.2%
- Shares Outstanding
- 7.75M
- Float Shares
- 7.45M
of shares held by institutions
286 13F filers
Buy/sell ratio 0.13. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.14M | ▲ 44.23K |
| Congress Asset Management Co | 578.77K | ▼ 108.67K |
| Wasatch Advisors LP | 552.81K | ▼ 130.45K |
| Neuberger Berman Group LLC | 537.04K | ▲ 236.44K |
| Vanguard Group Inc | 533.58K | ▲ 5.96K |
| Price T Rowe Associates Inc | 357.33K | ▲ 110.83K |
| Vanguard Capital Management LLC | 329.62K | ▲ 2.90K |
| Boston Trust Walden Corp | 320.34K | ▼ 15.94K |
| State Street Corp | 314.69K | ▲ 1.88K |
| Massachusetts Financial Services Co | 240.07K | ▲ 16.59K |
| Thrivent Financial For Lutherans | 238.89K | ▼ 500 |
| Geode Capital Management, LLC | 208.02K | ▲ 7.09K |
Held by 296 ETFs
Biggest fund positions in UFPT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 25, 26 | KOZIN MARC D | sell | 3,650 |
| Aug 25, 26 | KOZIN MARC D | sell | 3,350 |
| Aug 18, 26 | Hudson Symeria | sell | 298 |
| Aug 13, 26 | Hudson Symeria | other | 493 |
| Aug 13, 26 | Hudson Symeria | other | 703 |
| Aug 14, 26 | Hudson Symeria | sell | 1,926 |
| Aug 13, 26 | Hudson Symeria | other | 703 |
| Aug 13, 26 | Hudson Symeria | other | 493 |
| Aug 13, 26 | FELDMANN CYNTHIA L | sell | 1,000 |
| Jun 4, 26 | Hassett Joseph John | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our UFPT coverage
Recent articles, reports, and earnings notes.
No research on UFPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UFPT report →UFP Industries: Paying 2022's Price For Trough Earnings
seekingalpha.com · Nov 18
UFP Industries: Innovation-Led Growth And Margin Recovery Could Drive Upside
seekingalpha.com · Nov 9
UFP Industries Might Be Worsening, But It Still Offers Upside
seekingalpha.com · Nov 6
UFP Technologies: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 4
What UFP Technologies (UFPT) Said on Its Q3 Earnings Call
marketbeat.com · Nov 4
UFP Industries Names Scott Worthington Vice President of Investor Relations
prnewswire.com · Nov 4
UFP Technologies, Inc. (UFPT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
UFP Technologies (UFPT) Q3 Earnings and Revenues Surpass Estimates
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.